Homepage

Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries

Screening Compounds Building blocks

Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls

Company News & Media Contact us For suppliers Trends in discovery compounds

Homepage > Company > Media > Pharma News > 2018 > ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen

ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen

Read also

Pharma companies must adapt to keep pace with AI developments, say experts

Pharma companies must adapt to keep pace with AI developments, say experts

At the Outsourcing in Clinical Trials Conference, key opinion leaders shared predictions for workflow changes due to AI.

This Is Huge News for Novo Nordisk

This Is Huge News for Novo Nordisk

Novo Nordisk just released data from a clinical trial featuring its oral semaglutide treatment, Rybelsus. Rybelsus is an oral glucagon-like peptide-1 (GLP-1) agonist and sibling medication to ...

J&J, Eli Lilly pad immunology profiles with trial readouts in new patient groups

J&J, Eli Lilly pad immunology profiles with trial readouts in new patient groups

With new readouts, Johnson & Johnson's Tremfya and Eli Lilly's Ebglyss are further proving their worth in separate immunology areas. Key drugs from Johnson & Johnson and Eli Lilly stand to...

Taurine reduces atherosclerotic plaque area and stability in mice

Taurine reduces atherosclerotic plaque area and stability in mice

Previous studies suggest that taurine (2-aminoethanesulfonic acid) supplementation may attenuate atherosclerosis by reducing lipid levels. However, energy drinks containing taurine have been s...